Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial-Reference-Cited by-同舟云学术

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

Published:2016-01 Issue: Volume:244 Page:138-146
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Farnier Michel,Jones Peter,Severance Randall,Averna Maurizio,Steinhagen-Thiessen Elisabeth,Colhoun Helen M.,Du Yunling,Hanotin Corinne,Donahue Stephen

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference28 articles.

1. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Baigent;Lancet,2010

2. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines;Stone;Circulation,2014

3. Ezetimibe added to statin therapy after acute coronary syndromes;Cannon;N. Engl. J. Med.,2015

4. 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult;Anderson;Can. J. Cardiol.,2013

5. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia–full report;Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members;J. Clin. Lipidol.,2014

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN study;American Heart Journal;2024-11

2. Impact of PCSK9 Inhibitors on Lipoprotein(a): A Meta-analysis and Meta-regression of Randomized Controlled Trials;2024-07-11

3. Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study;BMC Medical Research Methodology;2024-06-22

4. Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials;Int. Journal of Clinical Pharmacology and Therapeutics;2024-06-01

5. The Essence of Lipoproteins in Cardiovascular Health and Diseases Treated by Photodynamic Therapy;Biomedicines;2024-04-26